7 Pulmonary Hypertension Headlines You Can’t Miss
1. 7 Medications to Treat Pulmonary Hypertension
This article is about which type of treatments or medications are available to help treat pulmonary hypertension. Check out a list of seven medications to treat pulmonary hypertension.
Read more about it here: https://bit.ly/1MvjrMz
2. 9 Tips for Exercising with Pulmonary Hypertension
This article unveils some advice for patients with pulmonary hypertension who would like to exercise. Check out the list to discover nine tips for exercising with pulmonary hypertension.
Read more about it here: https://bit.ly/1Mvjxns
3. 8 Common Signs of Pulmonary Hypertension
This article is focused on some common signs of pulmonary hypertension. To discover eight common sign of pulmonary hypertension, check out this list.
Read more about it: https://bit.ly/1MvjTdu
4. Women with PAH Found to Be Largely Sedentary, Amplifying Feelings of Fatigue
Women with pulmonary arterial hypertension (PAH) are often sedentary, and the lack of daily activity results in physical and mental feelings of low energy, according to a study published in the journal Chest. The study, “Physical Activity and Symptoms in Pulmonary Arterial Hypertension,” suggested that interventions to improve fatigue and other symptoms may lead to increased physical activity in PAH patients.
Read more about it: https://bit.ly/1Mvk74B
5. Heart Hormone Seen to Control Lung Blood Pressure, Impacting PAH, via Endothelial Cells
The cardiac hormone known as atrial natriuretic peptide (ANP), controls blood pressure both throughout the body and in the lungs. Researchers previously believed that ANP’s hypotensive effect in the lungs was mediated by changes in the smooth muscle that lines pulmonary blood vessels. But scientists now report that the hormone facilitates low blood pressure via the endothelial cells lining the blood vessels.
Read more about it: https://bit.ly/1ZovQnA
6. Actelion’s Uptravi (selexipag) Approved for PAH Patients in Australia and New Zealand
Actelion has announced that its orally active pulmonary arterial hypertension (PAH) drug, Uptravi (selexipag), has been approved for the treatment of PAH patients by both the Therapeutic Goods Administration of Australia and the New Zealand Medicines and Medical Devices Safety Authority.
Read more about it: https://bit.ly/21IKqWC
7. Researchers Identify 2 Possible Blood Biomarkers of PAH Progression and Severity
Galectin-3 (Gal-3) and the hormone aldosterone are two potential biomarkers for disease progression in patients with pulmonary arterial hypertension, according to a recent study, “Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension,” published in the journal Heart.
About the Author
